Senior insider sale
SVP-CHIEF DEVELOPMENT OFFICER at SANGAMO THERAPEUTICS, INC — senior position signals high conviction
$176.7K
588.71K shares
DUBOIS-STRINGFELLOW NATHALIE plans to sell 588.71K shares of SANGAMO THERAPEUTICS, INC valued at approximately $176.7K. Form 144 is a notice of intent to sell restricted or control securities — not a mandatory transaction. This filing provides advance warning of potential selling pressure.
Restricted Stock Units
Vested grant settled in stock; consideration was Reporting Person's continued service as an employee of the Issuer.
Restricted Stock Units
Vested grant settled in stock; consideration was Reporting Person's continued service as an employee of the Issuer.
Restricted Stock Units
Vested grant settled instock; consideration was Reporting Person's continued service as an employee ofthe Issuer.
ESPP Purchase
Cash
ESPP Purchase
Cash
Restricted Stock Units
Vested grant settled in stock; consideration was Reporting Person's continued service as an employee of the Issuer.
ESPP Purchase
Cash
ESPP Purchase
Cash
Restricted Stock Units
Vested grant settled in stock; consideration was Reporting Person's continued service as an employee of the Issuer.
ESPP Purchase
Cash
ESPP Purchase
Cash
Restricted Stock Units
Vested grant settled in stock; consideration was Reporting Person's continued service as an employee of the Issuer.
ESPP Purchase
Cash
Restricted Stock Units
Vested grant settled in stock; consideration was Reporting Person's continued service as an employee of the Issuer.
ESPP Purchase
Cash
ESPP Purchase
Cash
ESPP Purchase
Cash
ESPP Purchase
Cash
| Acquisition Date | Type | Amount Acquired | Gift |
|---|---|---|---|
2/25/2026 | Restricted Stock Units Vested grant settled in stock; consideration was Reporting Person's continued service as an employee of the Issuer. | 17.65K | — |
2/24/2026 | Restricted Stock Units Vested grant settled in stock; consideration was Reporting Person's continued service as an employee of the Issuer. | 32.62K | — |
1/22/2026 | Restricted Stock Units Vested grant settled instock; consideration was Reporting Person's continued service as an employee ofthe Issuer. | 438.76K | — |
11/28/2025 | ESPP Purchase Cash | 5K | — |
5/30/2025 | ESPP Purchase Cash | 5K | — |
2/25/2025 | Restricted Stock Units Vested grant settled in stock; consideration was Reporting Person's continued service as an employee of the Issuer. | 29.05K | — |
11/29/2024 | ESPP Purchase Cash | 5K | — |
5/31/2024 | ESPP Purchase Cash | 5K | — |
2/25/2024 | Restricted Stock Units Vested grant settled in stock; consideration was Reporting Person's continued service as an employee of the Issuer. | 15.19K | — |
11/30/2023 | ESPP Purchase Cash | 5K | — |
5/31/2023 | ESPP Purchase Cash | 5K | — |
2/25/2023 | Restricted Stock Units Vested grant settled in stock; consideration was Reporting Person's continued service as an employee of the Issuer. | 17.99K | — |
5/31/2022 | ESPP Purchase Cash | 3.12K | — |
2/25/2022 | Restricted Stock Units Vested grant settled in stock; consideration was Reporting Person's continued service as an employee of the Issuer. | 1.09K | — |
10/29/2021 | ESPP Purchase Cash | 322.00 | — |
5/28/2021 | ESPP Purchase Cash | 474.00 | — |
4/30/2021 | ESPP Purchase Cash | 1.80K | — |
10/30/2020 | ESPP Purchase Cash | 645.00 | — |
| Total | 588.71K | ||
Units to sell
588.71K
Market value
$176.7K
Units
588.71K
Value
$176.7K
| Date | Units to Sell | Approx. Market Value | Exchange | Status |
|---|---|---|---|---|
4/6/2026 | 588.71K | $176.7K | Nasdaq | Planned |
| Total | 588.71K | $176.7K | ||